Bifogade filer
20240730 Isofol_Isofol appoints new CFO_final
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive financial experience from biotech and pharmaceutical companies and will assume the position on August 13.
The information in the press release is intended for investors.
Margareta Hagman has long experience from CFO roles and other positions in both listed and unlisted companies within the pharmaceutical and biotech industry. Notably, she has been the Executive Vice President and Chief Financial Officer (CFO) at BioGaia AB. She has also been the CFO at Xbrane Biopharma AB and Ortivus AB and is a board member at Infant Bacterial Therapeutics AB – all companies listed on Nasdaq Stockholm.
Margareta Hagman holds a degree in Business and Economics from Örebro University, Sweden.
Margareta Hagman succeeds Magnus Hurst, who has been Isofol’s CFO on a consultancy basis since January 2024 and is leaving the company for parental leave. Magnus will remain with the company during a transition period to ensure a smooth handover.
"I am very pleased to welcome Margareta as CFO to Isofol and look forward to working together with her. I am convinced that she, with her solid background and broad experience, will be a tremendous asset to Isofol on the journey ahead. I also want to thank Magnus for his valuable contributions," says Isofol's CEO, Petter Segelman Lindqvist.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, CEO
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 CET on July 30, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.